{"id":"https://openalex.org/W3030880997","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps1105","title":"A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.","display_name":"A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3030880997","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps1105","mag":"3030880997"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.tps1105","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps1105","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps1105","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara M. Tolaney","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071675004","display_name":"Guy J\u00e9rusalem","orcid":"https://orcid.org/0000-0002-8845-0043","observed_orcids":["https://orcid.org/0000-0002-8845-0043"]},"institutions":[{"id":"https://openalex.org/I157674565","display_name":"University of Li\u00e8ge","ror":"https://ror.org/00afp2z80","country_code":"BE","type":"education","lineage":["https://openalex.org/I157674565"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Guy Jerusalem","raw_affiliation_strings":["CHU Sart Tilman and Li\u00e8ge University, Li\u00e8ge, Belgium;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHU Sart Tilman and Li\u00e8ge University, Li\u00e8ge, Belgium;","institution_ids":["https://openalex.org/I157674565"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016015665","display_name":"Roberto Salgado","orcid":"https://orcid.org/0000-0002-1110-3801","observed_orcids":["https://orcid.org/0000-0002-1110-3801"]},"institutions":[{"id":"https://openalex.org/I4210093878","display_name":"GZA Ziekenhuizen Campus Sint-Augustinus","ror":"https://ror.org/00kss4e25","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I4210093878","https://openalex.org/I4405261247"]},{"id":"https://openalex.org/I4405267518","display_name":"GZA Ziekenhuizen","ror":"https://ror.org/033f1am78","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I4405267518"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Roberto Salgado","raw_affiliation_strings":["GZA-ZNA Hospitals, Antwerp, Belgium;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GZA-ZNA Hospitals, Antwerp, Belgium;","institution_ids":["https://openalex.org/I4210093878","https://openalex.org/I4405267518"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100367880","display_name":"Xiaochun Liu","orcid":"https://orcid.org/0000-0002-9071-5434","observed_orcids":["https://orcid.org/0000-0002-9071-5434"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaochun Liu","raw_affiliation_strings":["Bristol-Myers Squibb, Lawrence, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Lawrence, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100362230","display_name":"Tian Chen","orcid":"https://orcid.org/0000-0001-8490-600X","observed_orcids":["https://orcid.org/0000-0001-8490-600X"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tian Chen","raw_affiliation_strings":["Bristol-Myers Squibb, Lawrence, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Lawrence, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100379708","display_name":"Hongxia Zhang","orcid":"https://orcid.org/0000-0001-6117-917X","observed_orcids":["https://orcid.org/0000-0001-6117-917X"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hongxia Zhang","raw_affiliation_strings":["Bristol-Myers Squibb, Lawrence, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Lawrence, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076735661","display_name":"Mustimbo E. P. Roberts","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mustimbo Roberts","raw_affiliation_strings":["Bristol-Myers Squibb, Lawrence, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Lawrence, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107832821","display_name":"Dimitrios Zardavas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dimitrios Zardavas","raw_affiliation_strings":["Bristol-Myers Squibb, Lawrence, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Lawrence, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089513581","display_name":"Aleix Prat","orcid":"https://orcid.org/0000-0003-2377-540X","observed_orcids":["https://orcid.org/0000-0003-2377-540X"]},"institutions":[{"id":"https://openalex.org/I4210115097","display_name":"Hospital Cl\u00ednic de Barcelona","ror":"https://ror.org/02a2kzf50","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210115097"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Aleix Prat","raw_affiliation_strings":["Hospital Clinic, Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Clinic, Barcelona, Spain;","institution_ids":["https://openalex.org/I4210115097"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"TPS1105","last_page":"TPS1105"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":1.0},{"id":"https://openalex.org/keywords/anastrozole","display_name":"anastrozole","score":1.0},{"id":"https://openalex.org/keywords/cdk4-6-inhibition","display_name":"CDK4/6 inhibition","score":0.7910000085830688},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.9390000104904175},{"id":"https://openalex.org/keywords/estrogen-receptor-positive-breast-cancer","display_name":"estrogen receptor-positive breast cancer","score":0.8460000157356262},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/primary-breast-cancer","display_name":"primary breast cancer","score":0.8289999961853027},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.8690000176429749},{"id":"https://openalex.org/keywords/postmenopausal-patients","display_name":"postmenopausal patients","score":0.7599999904632568},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.8330000042915344},{"id":"https://openalex.org/keywords/residual-cancer-burden","display_name":"residual cancer burden","score":0.7630000114440918},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.9290000200271606},{"id":"https://openalex.org/keywords/breast-conserving-surgery","display_name":"breast-conserving surgery","score":0.9129999876022339}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9283386468887329},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6201173663139343},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5834226012229919},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5523791313171387},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.5268734097480774},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5139243602752686},{"id":"https://openalex.org/C2776215463","wikidata":"https://www.wikidata.org/wiki/Q419143","display_name":"Anastrozole","level":5,"score":0.4808967113494873},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.46292874217033386},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.42359286546707153},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.4176754951477051},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3883094787597656},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.32852882146835327},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.29946979880332947},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.24711468815803528},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2447030246257782},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2369770109653473}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.tps1105","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps1105","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps1105","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8700000047683716,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3046322188","https://openalex.org/W3216352272","https://openalex.org/W2805222254","https://openalex.org/W2793093901","https://openalex.org/W2599190269","https://openalex.org/W2898919491","https://openalex.org/W2592055551","https://openalex.org/W2317465324","https://openalex.org/W3093743109","https://openalex.org/W3030880997"],"abstract_inverted_index":{"TPS1105":[0],"Background:":[1],"Cyclin-dependent":[2],"kinase":[3],"4/6":[4,34],"(CDK":[5],"4/6)":[6],"inhibition":[7,35],"coupled":[8],"with":[9,21,53,82,141,150,189],"ER":[10],"signaling":[11],"blockade":[12],"is":[13,65,249],"an":[14],"efficient":[15],"treatment":[16,112,241],"approach":[17],"for":[18,91,157],"patients":[19],"(pts)":[20],"metastatic":[22],"hormone":[23],"receptor-positive,":[24],"HER2\u2212":[25,84,148],"BC.":[26,86],"Preclinical":[27],"data":[28],"suggest":[29],"synergistic":[30],"activity":[31],"of":[32,56,110,165,187,191,208,235],"CDK":[33],"and":[36,47,121,131,139,161,178,197,217,225,238],"PD-1":[37],"blockade;":[38],"in":[39,79,95,104],"a":[40,66,105],"syngeneic":[41],"mouse":[42],"tumor":[43,49,122,152,169],"model,":[44],"improved":[45],"efficacy":[46],"complete":[48,220],"regression":[50],"were":[51],"observed":[52],"phased":[54],"administration":[55],"ABE":[57],"+":[58,75],"PD-L1":[59,117],"therapy.":[60],"Methods:":[61],"CheckMate":[62],"7A8":[63],"(NCT04075604)":[64],"randomized,":[67],"noncomparative,":[68],"multicenter,":[69],"phase":[70],"2":[71,154],"study":[72,248],"evaluating":[73],"PAL":[74],"ANA":[76],"+/-":[77],"NIVO":[78,92],"postmenopausal":[80,137],"pts":[81,100,127,135,188],"ER+,":[83,147],"primary":[85,151],"After":[87],"determining":[88],"safe":[89],"doses":[90],"combination":[93],"regimens":[94],"the":[96],"safety":[97,132,216],"run-in":[98,195],"phase,":[99],"will":[101,128],"be":[102],"randomized":[103],"4:4:3":[106],"ratio":[107],"to":[108,173],"1":[109],"3":[111],"arms":[113],"(Table)":[114],"stratified":[115],"by":[116,203],"expression,":[118],"node":[119],"status":[120],"size.":[123],"Following":[124],"treatment,":[125],"all":[126],"undergo":[129,174],"surgery":[130,210,227],"follow-up.":[133],"Eligible":[134],"are":[136,185,245],"women":[138],"men":[140],"newly":[142],"diagnosed,":[143],"untreated,":[144],"histologically":[145],"confirmed":[146],"BC":[149],"\u2265":[153],"cm;":[155],"suitable":[156],"neoadjuvant":[158],"endocrine":[159],"monotherapy":[160],"surgery;":[162],"ECOG":[163],"PS":[164],"0\u20131;":[166],"have":[167],"baseline":[168],"tissue":[170,179],"available;":[171],"willing":[172],"on-treatment":[175],"research":[176],"biopsy":[177],"collection":[180],"at":[181,206],"surgery.":[182],"Primary":[183],"endpoints":[184,214,231],"number":[186],"occurrence":[190],"dose-limiting":[192],"toxicity":[193],"(safety":[194],"phase)":[196],"residual":[198],"cancer":[199],"burden":[200],"0\u2013I":[201],"rate":[202,224],"central":[204],"assessment":[205],"time":[207],"definitive":[209],"(randomized":[211],"phase).":[212],"Secondary":[213],"include":[215,232],"tolerability,":[218],"pathologic":[219],"response,":[221],"objective":[222],"response":[223],"breast-conserving":[226],"rate.":[228],"Key":[229],"exploratory":[230],"biomarkers":[233],"indicative":[234],"pharmacodynamic":[236],"changes":[237],"potentially":[239],"predicting":[240],"sensitivity.":[242],"Interim":[243],"analyses":[244],"planned.":[246],"The":[247],"currently":[250],"enrolling.":[251],"Clinical":[252],"trial":[253],"information:":[254],"NCT04075604":[255],".":[256],"[Table:":[257],"see":[258],"text]":[259]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2025-10-10T00:00:00"}